Bepirovirsen Clinical Trials (2026): 9 Studies for Hepatitis B & Chronic Hepatitis B
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
9 Bepirovirsen clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Hepatitis B & Chronic Hepatitis B) and 3,036 total planned enrollment. 2 Phase 3 Bepirovirsen trials and 3 Phase 2 are listed. 1 Bepirovirsen clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT04954859 (Feb 2029).
Where to Participate: All Bepirovirsen Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Bepirovirsentrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | GSK Investigational Site | Sacramento95817 | NCT04954859 | Map |
| MA | GSK Investigational Site | Boston02114 | NCT04954859 | Map |
| MI | GSK Investigational Site | Detroit48202 | NCT04954859 | Map |
Bepirovirsen clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| P1 | 1 | 2 | 3 | ||
| P1/P2 | 1 | 1 | |||
| P2 | 1 | 2 | 3 | ||
| P3 | 2 | 2 |
Recruiting Bepirovirsen clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04954859 | B-SureLong-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) | P2 | Hepatitis B | 450 | Dec 2021 |
Bepirovirsen clinical trials by indication
Hepatitis B (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04954859 | B-Sure | P2 | recruiting | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) |
| NCT06497504 | B-Focus | P2 | active not recruiting | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) |
| NCT07168356 | B-Kind | P1 | active not recruiting | A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease |
| NCT05330455 | — | P1/P2 | terminated | Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection |
| NCT06422767 | — | P1 | completed | Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers |
| NCT06058390 | — | P1 | completed | A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants |
Chronic Hepatitis B (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05630807 | B-Well 1 | P3 | completed | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) |
| NCT05630820 | B-Well 2 | P3 | completed | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) |
Chronic Hepatitis B Virus Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06537414 | B-UNITED | P2 | active not recruiting | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
Bepirovirsen pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| B-Well 1 | NCT05630807 | P3 | completed | Chronic Hepatitis B | 981 | — |
| B-Well 2 | NCT05630820 | P3 | completed | Chronic Hepatitis B | 857 | — |
| B-Sure | NCT04954859 | P2 | recruiting | Hepatitis B | 450 | — |
| B-UNITED | NCT06537414 | P2 | active not recruiting | Chronic Hepatitis B Virus Infection | 283 | PMID 40562220 |
| B-Focus | NCT06497504 | P2 | active not recruiting | Hepatitis B | 153 | — |
Terminated and withdrawn Bepirovirsen trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05330455terminatedStudy of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
All Bepirovirsen trials (9)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04954859 | B-Sure | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) | P2 | recruiting | 450 | GlaxoSmithKline | Dec 2021 |
| NCT06537414 | B-UNITED | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | P2 | active not recruiting | 283 | GlaxoSmithKline | Nov 2024 |
| NCT06497504 | B-Focus | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | P2 | active not recruiting | 153 | GlaxoSmithKline | Sep 2024 |
| NCT07168356 | B-Kind | A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease | P1 | active not recruiting | 32 | GlaxoSmithKline | Sep 2025 |
| NCT05630807 | B-Well 1 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | P3 | completed | 981 | GlaxoSmithKline | Dec 2022 |
| NCT05630820 | B-Well 2 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | P3 | completed | 857 | GlaxoSmithKline | Dec 2022 |
| NCT05330455 | Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection | P1/P2 | terminated | 74 | GlaxoSmithKline | Apr 2022 | |
| NCT06422767 | Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers | P1 | completed | 46 | GlaxoSmithKline | Jul 2024 | |
| NCT06058390 | A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants | P1 | completed | 160 | GlaxoSmithKline | Oct 2023 |
Bepirovirsen clinical trials: frequently asked questions
- How many Bepirovirsen clinical trials are there?
- 9 Bepirovirsen clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 4 are marked completed.
- Are Bepirovirsen clinical trials recruiting in 2026?
- Yes — 1 Bepirovirsen trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Bepirovirsen being studied for?
- Bepirovirsen is being studied for Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Chronic Hepatitis B Virus Infection. The trials are grouped by indication on this page.
- What phase is Bepirovirsen in?
- Bepirovirsen clinical trials span 2 Phase 3, 3 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Bepirovirsen clinical trials?
- The lead sponsor across the most Bepirovirsen trials is GlaxoSmithKline. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Bepirovirsenas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: